Clonidine extended-release - Onxeo

Drug Profile

Clonidine extended-release - Onxeo

Alternative Names: BA-028; Clonidine Lauriad; Clonidine MBT; Clonidine XR; Validive

Latest Information Update: 30 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator BioAlliance Pharma
  • Developer Onxeo SA
  • Class Analgesics; Anti-inflammatories; Antiglaucomas; Antimigraines; Centrally-acting antihypertensives; Chlorobenzenes; Imidazolines; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists; Imidazoline receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stomatitis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Stomatitis

Most Recent Events

  • 07 Oct 2016 Safety and pharmacokinetic data from the phase I trial in Stomatitis (In volunteers) presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 01 Apr 2016 Onxeo completes a phase I trial for Stomatitis (In volunteers) in United Kingdom (NCT02548806)
  • 21 Oct 2015 Patient compliance and acceptability data from a phase II trial in Stomatitis presented at the 57th Annual Meeting of the American Society for Radiation Oncology (ASTRO-2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top